|
Biotecnologia Aplicada
Elfos Scientiae
ISSN: 0684-4551
Vol. 12, Num. 2, 1995, pp. 72
|
Revista Biotecnologia Aplicada 12(2): 72 (1995)
REPORTE CORTO/SHORT REPORT
Presented in the Congress Biotecnologia Habana 94. La Habana,
Cuba, Nov. 28 - Dec. 3, 1994
CLONING, EXPRESSION AND CHARACTERIZATION OF THE P64k OUTER
MEMBRANE PROTEIN FROM N. meningitidis
Gerardo Guillen^1, Ricardo Silva^1, Anabel Alvarez^1, Lidia I.
Novoa^1, Sonia Gonzalez^1, Alexis Musacchio^1, Manuel Selman^1,
Alejandro Martin^1, Vivian Morera^2, Julio Fernandez^1, Juan
Morales^1, Gustavo Sierra^1, Vladimir Besada^2, Edelgis
Coizeau^1, Evelyn Caballero^1, Consuelo Nazabal^1, Tania
Carmenate^1, Olivia Niebla^1, Jesus del Valle^1, Beatriz
Tamargo^1, Javier Gonzalez^2, Regla Estrada^2, Yanet Tambara^2,
Gabriel Padron^2, and Luis Herrera^1.
^1Division of Vaccines and ^2Division of Physics-Chemistry,
Center for Genetic Engineering and Biotechnology, P.O. Box 6162,
Havana-Cuba.
Code Number: BA95013
File Sizes:
Text: 5K
No associated graphics
INTRODUCTION
Meningococcal meningitis as an endemic disease occurs with a
frequency of approximately 0.5-5 per 100 000 per year in a great
part of the world. Epidemic disease has been reported from all
continents in the last few years.
The serogroups A, B and C are the main cause of the disease. The
group B N. meningitidis polysaccharide (PS) in contrast
to group A, C, and others is a poor immunogen in humans due to
immunological tolerance and structural similarities that have
been found in developing fetal brain tissue (1-2). Therefore, the
strategy of vaccine against serogroup B should be based in
strains of N. meningitidis, could be an effective approach
to confer protection against meningococcal disease in humans.
EXPERIMENTAL PROCEDURES
Restriction enzymes, T4 DNA ligase, Klenow fragment of DNA
polymerase I and Exonuclease III were obtained from Heber Biotec
(Cuba). The oligonucleotides and the adapter were synthesized at
Heber Biotec. The [alpha32-P]dATP, the Multiwell microtitre plate
DNA sequencing system-T7 DNA plolymerase, peroxidase-conjugated
streptavidin and anti-human, rabbit and mouse biotinilated
antibodies were purchased from Amersham (UK). The chemicals were
of the highest grade commercially available. All the procedures
were performed following manufacturing instructions or as in (3).
The complete amino acid sequence of P64k was obtained using
automatic sequencing and mass-spectrometry.
RESULTS AND DISCUSSION
The gene M-6, encoding the high molecular weight protein P64k,
was isolated from a genomic library of the N. meningitidis
strain B385, constructed in the EMBL-3 vector. This library was
screened using a rabbit hyperimmune serum raised against a
purified fraction of high molecular weight proteins. The clone
31 was selected for further study on western blotting, with a
pool of sera from convalescent people to meningococcemia.
The DNA insert containing the entire M-6 gene was subcloned and
sequenced. Then the M-6 gene was expressed in E. coli as
a fusion protein with the N-terminal of interleukine-2, under the
control of tryptophan promoter. P64k was also produced as a
non-fusion protein.
The expression of P64k was shown on PAGE and Western-blotting
using rabbit polyclonal antibodies against the whole outer
membrane mixture from N. meningitidis. MAbs obtained
against the recombinant protein recognized the natural protein
on Western-blotting. The recombinant protein is also recognized
by serum from convalescent patients to meningococcal disease.
The MAb 114 was assayed in ELISA with a panel of 85 N.
meningitidis strains. The protein was recognised in 81
strains (95.3%). The strains that were not recognised, were
neither epidemic nor isolates from systemic disease. The
predicted amino acid sequence of the M-6 gene showed complete
homology when compared with the amino acid sequence from the
recombinant protein.
The P64k protein has been expressed in E. coli. None of
other antigens: Tbp1, class 1, class 3 and class 5C has been
possible to express as a non-fusion protein at high levels, under
the control of tryptophan promoter in our laboratory.
REFERENCES
1. FINNE, K. et al. (1983). Lancet 2:
355-357
2. GRIFFISS, J. M. et al. (1991). Transaction Royalty
Soc. Trop. Med. and Hygiene 85 (Suppl 1): 32-36
3. SAMBROOK et al. (1989). Molecular Cloning: A
Laboratory Manual, 2nd ed. Cold Spring Harbor Laboratory
Press, USA.
Copyright 1995 Sociedad Iberolatinoamericana de Biotecnologia
Aplicada a la Salud
|